Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $1.52M rose 26.5% year over year, behind the +64.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 35.1% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.
Context
- Stock-based compensation amounted to 6.9% of revenue in FY2025, down 1.2 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +26.5% toward the trailing-twelve-month pace of +64.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 5.51M USD
- Year-over-year change
- +74.2%
- 4-year CAGR
- +13.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.51M | +74.2% |
| FY2024 | 2024-12-31 | 3.17M | +0.9% |
| FY2023 | 2023-12-31 | 3.14M | -25.6% |
| FY2022 | 2022-12-31 | 4.22M | +24.8% |
| FY2021 | 2021-12-31 | 3.38M | — |
Stock-Based Compensation vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 stock-based compensation of $5.83M is the 8th largest of the 10 companies compared; the peer median is $12.55M.
- Its year-over-year change of +64.5% is the 2nd highest of 10, against a peer median of +2.5%.
- Stock-based compensation amounts to 6.7% of revenue for ETON, versus a peer median of 12.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.83M | -11.3% | +5.5% | 21.3% | |
| LTM Sep 2026 | $132.29M | +4.4% | +10.1% | 13.8% | |
| LTM Sep 2026 | $72.84M | +70.9% | +5.6% | 11.2% | |
| LTM Mar 2026 | $12.62M | -20.6% | +43.3% | 10.3% | |
| LTM Mar 2026 | $12.55M | +2.5% | +2.8% | 18.0% | |
| LTM Mar 2026 | $7.15M | -15.9% | +1.9% | — | |
| LTM Mar 2026 | $6.24M | +33.6% | +18.6% | 12.2% | |
| LTM Mar 2026 | $5.83M | +64.5% | +9.3% | 6.7% | |
| LTM Mar 2026 | $3.48M | -33.4% | — | 0.9% | |
| LTM Mar 2026 | $2.79M | +13.0% | +36.8% | — | |
| Peer median (excluding ETON) | $12.55M | +2.5% | +7.8% | 12.2% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| Deferred Income Tax | (546K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.38M | 4.22M | 3.14M | 3.17M | 5.51M |
| Change in Working Capital | (6.21M) | 7.66M | 3.53M | (698K) | (859K) |
| Accounts Receivables | (5.42M) | 3.62M | (1.56M) | (3.12M) | (6.4M) |
| Inventory | 692K | (7K) | (354K) | (1.31M) | (5.88M) |
| Accounts Payables | (570K) | (8K) | 53K | 2.32M | 6.81M |
| Other Working Capital | (910K) | 4.06M | 5.39M | 1.41M | 4.61M |
| Other Non-Cash Items | 148K | 189K | 184K | 1.18M | 6.43M |
| Operating Cash Flow | (4.72M) | 4.82M | 6.82M | 969K | 10.52M |
| Capital Expenditures | (3.26M) | (2.79M) | (775K) | (26K) | (333K) |
| Acquisitions (Net) | 700K | 0 | 0 | (30M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (2.75M) | 0 | (9.99M) | 0 |
| Investing Cash Flow | (2.56M) | (2.79M) | (775K) | (40.01M) | (333K) |
| Debt Repayment | (150K) | (385K) | (1.16M) | 24.15M | 0 |
| Common Stock Issued | 541K | 0 | 0 | 8.19M | 598K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 251K | 198K | 248K | 217K |
| Financing Cash Flow | 391K | (134K) | (957K) | 32.59M | 815K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.89M) | 1.9M | 5.08M | (6.45M) | 11.01M |
| Free Cash Flow | (7.98M) | 2.03M | 6.04M | 943K | 10.19M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.